China's Harbin Pharmaceutical Group Co. Ltd. said its controlling shareholder was considering an overseas listing.

Harbin Pharmaceutical Group Ltd., which controls a 34.76 percent stake in the Shanghai-listed company, is drafting an overseas listing plan.

Harbin Pharmaceutical Group Ltd. also holds 44.82 percent of Sanjing Pharmaceutical. Trading in the A-shares of Harbin Pharmaceutical was suspended on Jan 22 as the Shanghai stock exchange asked it to clarify the media report. The stock has gained nearly 90 percent in the past year.

Source:未知